BiomX (PHGE) Common Equity (2018 - 2026)
BiomX (PHGE) posted Common Equity of -$881000.0 for Q1 2026, up 32.33% sequentially from -$1.3 million in Q4 2025, and down 103.6% YoY from $24.5 million in Q1 2025.
BiomX (PHGE) Common Equity (2018 - 2026) Analysis & Trends
BiomX has reported Common Equity for 9 years, with the latest figure at -$881000.0 in Q1 2026.
- Quarterly Common Equity fell 103.6% year-over-year to -$881000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$881000.0 (down 103.6% YoY) and the FY2025 annual result came in at -$1.3 million, down 105.39% from the prior year.
- Common Equity improved to -$881000.0 in Q1 2026 per PHGE's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Common Equity peaked at $40.0 million in Q1 2022 and troughed at -$1.3 million in Q4 2025.
- A 5-year average of $18.2 million and a median of $19.2 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity jumped 683.77% in 2024, then plunged 105.39% in 2025.
- Over 5 years, Common Equity stood at $21.0 million in 2022, then sank by 85.36% to $3.1 million in 2023, then surged by 683.77% to $24.1 million in 2024, then slumped by 105.39% to -$1.3 million in 2025, then surged by 32.33% to -$881000.0 in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$881000.0, -$1.3 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -881,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -881,000.00 |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 10.49 Mn |
| Jun 30, 2025 | 19.16 Mn |
| Mar 31, 2025 | 24.50 Mn |
| Dec 31, 2024 | 24.15 Mn |
| Sep 30, 2024 | 37.90 Mn |
| Jun 30, 2024 | 27.43 Mn |
| Mar 15, 2024 | 3.75 Mn |
| Dec 31, 2023 | 3.08 Mn |
| Sep 30, 2023 | 8.15 Mn |
| Jun 30, 2023 | 15.87 Mn |
| Mar 31, 2023 | 16.15 Mn |
| Dec 31, 2022 | 21.04 Mn |
| Sep 30, 2022 | 26.56 Mn |
| Jun 30, 2022 | 32.74 Mn |
| Mar 31, 2022 | 40.02 Mn |
| Dec 31, 2021 | 47.54 Mn |
| Sep 30, 2021 | 53.43 Mn |
| Jun 30, 2021 | 48.59 Mn |